Novo Nordisk said Thursday that its growth hormone formulation Norditropin (ingredient: somatropin) took the largest market share in 27 major countries in June. 

According to various international market research firms, including IQVIA and GERS, Norditropin dominated the growth hormone market in 27 countries in America, Europe, Asia, and Africa, accounting for 36.0 percent of total prescriptions in value terms and 29.2 percent in volume terms.

In the Korean growth hormone market, the second-quarter sales of Norditropin grew from 11.6 billion won ($9.91 million) in 2019 to 17.6 billion won in 2020 and 21.9 billion won in 2021.

"We are very glad that Norditropin placed top in the global growth hormone market," said Rana Azfar Zafar, vice president, and general manager at Novo Nordisk. "Our continuous research and development of formulations to enhance convenience for patients with growth hormone-related diseases have finally borne fruits."

Novo Nordisk received initial approval of the Norditropin injection from the U.S. Food and Drug Administration in 1987, marking the 33rd anniversary of its launch.

Korea also approved the medicine in 2004 and used Norditropin manufactured in Denmark, where Novo Nordisk's headquarters is located.